Related Experiment Video

Updated: Aug 15, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

483

Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors

Ting Yan1, Lun Yu2, Dangang Shangguan1

  • 1Department of Pharmacy, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410011, China.

International Immunopharmacology
|January 1, 2023
PubMed

Insights

Immune checkpoint inhibitors (ICIs), particularly targeting PD-1/PD-L1, enhance antitumor immunity. This review details their pharmacokinetics and pharmacodynamics for optimal clinical use in cancer therapy.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Immune checkpoint inhibitors (ICIs) are crucial in cancer therapy, improving outcomes across various malignancies.
  • The programmed cell death protein-1 (PD-1) / ligand 1 (PD-L1) pathway is a key target for enhancing antitumor immunity within the tumor microenvironment (TME).

Purpose of the Study:

  • To review pharmacokinetic and pharmacodynamic properties of PD-1/PD-L1 inhibitors.
  • To provide a reference for the rational clinical application of these immunotherapies.

Main Methods:

  • Literature review of pharmacokinetic and pharmacodynamic studies on PD-1/PD-L1 inhibitors.
  • Analysis of drug characteristics, including molecular weight and specific pharmacodynamic profiles.

Main Results:

  • ICIs, including PD-1/PD-L1 inhibitors, demonstrate significant benefits in monotherapy and combination therapies.
  • Distinct pharmacokinetic and pharmacodynamic profiles exist among different ICIs.
  • Regulatory approvals by FDA and NMPA highlight the efficacy of ICIs for various indications.

Conclusions:

  • Understanding the pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors is essential for effective clinical application.
  • This review serves as a guide for optimizing the use of these immunotherapies in cancer treatment.
Keywords:
PD-1PD-L1PharmacodynamicPharmacokinetic

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.8K

Related Concept Videos

Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
1.5K
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
499
Nonlinear Pharmacokinetics: Role of Transporters01:27

Nonlinear Pharmacokinetics: Role of Transporters

A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
81
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding01:22

Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding

When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
233
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Pharmacokinetics: Overview01:10

Pharmacokinetics: Overview

Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
6.7K